Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Liver organoids: Current advances and future applications for hepatology

Yohan Kim, Minseok Kang, Michael Girma Mamo, Michael Adisasmita, Meritxell Huch, Dongho Choi

Clin Mol Hepatol. 2025;31(Suppl):S327-S348. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1040

View: 1439 Download: 223

Prediction and management of small-for-size syndrome in living donor liver transplantation

Jia-hao Law, Alfred Wei-Chieh Kow

Clin Mol Hepatol. 2025;31(Suppl):S301-S326. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0870

View: 645 Download: 81

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation

Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia

Clin Mol Hepatol. 2025;31(Suppl):S285-S300. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0323

View: 1397 Download: 160 Crossref: 1

Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications

Jaeho Park, Yi-Te Lee, Vatche G. Agopian, Jessica S Liu, Ekaterina K. Koltsova, Sungyong You, Yazhen Zhu, Hsian-Rong Tseng, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S255-S284. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0541

View: 1293 Download: 167

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S228-S254. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0824

View: 3216 Download: 602 Crossref: 2

Prediction and prevention of post-procedural bleedings in patients with cirrhosis

Alix Riescher-Tuczkiewicz, Pierre-Emmanuel Rautou

Clin Mol Hepatol. 2025;31(Suppl):S205-S227. Published online February 18, 2025

DOI: https://doi.org/10.3350/cmh.2024.0928

View: 1053 Download: 126

Hepatitis E as a trigger for acute-on-chronic liver failure

Maria Buti, Juan Carlos Ruiz-Cobo, Rafael Esteban, Mar Riveiro-Barciela

Clin Mol Hepatol. 2025;31(Suppl):S196-S204. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0758

View: 1133 Download: 121

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 1329 Download: 142 Crossref: 1

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 3199 Download: 284 Crossref: 3

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 5637 Download: 201 Crossref: 2

Special Issue

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0045

View: 637 Download: 97

Reply to Correspondence

Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Clin Mol Hepatol. 2025;31(1):e117-e118. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0994

View: 675 Download: 19

Correspondence

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e110-e112. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0828

View: 866 Download: 47

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Gi-Ae Kim, Seung Won Choi, Young-Suk Lim

Clin Mol Hepatol. 2025;31(1):e108-e109. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0619

View: 895 Download: 31

Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”

Hee Yeon Kim, Miyoung Choi, Dae Won Jun

Clin Mol Hepatol. 2025;31(1):e105-e107. Published online November 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0937

View: 602 Download: 22

Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

Moon Haeng Hur, Yoon Jun Kim

Clin Mol Hepatol. 2025;31(1):e93-e95. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0943

View: 811 Download: 32

Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”

Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e84-e86. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0830

View: 781 Download: 31

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e81-e83. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0829

View: 830 Download: 33 Crossref: 1

Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”

Satya Priya Sharma, Ki Tae Suk

Clin Mol Hepatol. 2025;31(1):e74-e77. Published online October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0872

View: 1047 Download: 46

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Baokai Sun, Likun Zhuang

Clin Mol Hepatol. 2025;31(1):e67-e69. Published online September 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0744

View: 842 Download: 74

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”

Young Eun Chon, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e61-e63. Published online October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0878

View: 808 Download: 25

Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Young-Joo Jin, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e55-e57. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0846

View: 750 Download: 20 Crossref: 1

Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e52-e54. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0815

View: 793 Download: 28

Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”

Hee Yeon Kim, Miyoung Choi, Dae Won Jun

Clin Mol Hepatol. 2025;31(1):e48-e51. Published online September 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0777

View: 777 Download: 23

Letter to the Editor

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes

Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen

Clin Mol Hepatol. 2025;31(1):e35-e38. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0719

View: 910 Download: 62

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0602

View: 881 Download: 45 Crossref: 1

Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”

Wei Feng, Qile Wang, Qingwang Ye

Clin Mol Hepatol. 2025;31(1):e21-e22. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0887

View: 906 Download: 27

Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Xiao-Song Li, Xi-Ping Shen, Hang Li

Clin Mol Hepatol. 2025;31(1):e15-e16. Published online September 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0784

View: 839 Download: 37 Crossref: 1

Snapshot

Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues

Clara Meda, Arianna Dolce, Sara Della Torre

Clin Mol Hepatol. 2025;31(1):327-332. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0419

View: 937 Download: 78

Editorial

The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study”

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2025;31(1):316-318. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0847

View: 812 Download: 51

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 7184	MAFLD: How is it different from NAFLD?
Viewed By 6633	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5466	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5257	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4734	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 269	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 181	MAFLD: How is it different from NAFLD?
Cited By 93	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 88	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search